Clinical Trials Logo

HIV Seropositivity clinical trials

View clinical trials related to HIV Seropositivity.

Filter by:

NCT ID: NCT02935296 Completed - HIV Positive Clinical Trials

Integrated Treatment and Prevention for People Who Inject Drugs

Start date: February 2015
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine the feasibility of a future trial that will assess whether an integrated intervention combining psychosocial counseling and supported referrals for antiretroviral therapy (ART) at any CD4 cell count and substance use treatment for HIV-infected people who inject drugs (PWID) will reduce HIV transmission to HIV-uninfected injection partners, as compared to routine care dictated by national guidelines for HIV-infected PWID.

NCT ID: NCT02848586 Terminated - HIV Seropositivity Clinical Trials

Effects of E-cigarettes (ECIGs) on Pulmonary Inflammation and Behavior in HIV Infected Smokers

Start date: August 2016
Phase: N/A
Study type: Interventional

The purpose of this study is to determine if using e-cigarettes (ECIG) rather than regular tobacco cigarettes alters lung inflammation in people with and without HIV. The study is also interested in asking subjects their opinion on the use of ECIG and how they make them feel. This study is for research purposes only and is not intended to treat asthma or HIV or to modify tobacco use.

NCT ID: NCT02676167 Completed - HIV Clinical Trials

Public Health Targeting of PrEP at HIV Positives' Bridging Networks

SOPHOCLES
Start date: January 2017
Phase: N/A
Study type: Interventional

This developmental research grant award (R21) requests funds to explore the feasibility and impact of a public health system PrEP intervention in a recently emerging HIV epidemic in Athens Greece. The investigators propose a modeling approach using an Agent Based Model (ABM) that moves beyond basic pathogen and transmission patterns to dealing with complex social interactions, including overlapping social and sexual networks as well as implementation realities, like finite PrEP resources, delayed linkage to PrEP care and early PreP care retention based upon empirically collected data in Athens Greece.

NCT ID: NCT02590354 Completed - HIV-1 Infection Clinical Trials

Analytical Treatment Interruption in HIV Positive Patients

ISALA
Start date: January 25, 2016
Phase: N/A
Study type: Interventional

HIV-1 infected patients with normal peripheral blood CD4+ T-cell counts and undetectable viral load will be recruited in four Belgian HIV reference centers. Selected patients will undergo a two-step screening in which a viral reservoir measurement will be performed and among those with a very low viral reservoir an analytical treatment interruption of their longstanding antiretroviral therapy (ART). There is no randomization foreseen. Patients will receive an intense clinical and laboratory follow-up during 48 weeks followed by 12 weeks post intervention.

NCT ID: NCT02535429 Completed - Clinical trials for HIV-positive Diagnosis

Massage Therapy for HIV-positive People : Effects on Anxiety, Depression, Hyperventilation and Quality of Life

Start date: July 2015
Phase: N/A
Study type: Interventional

Massage therapy during 1 month and evaluation of depression, hyperventilation, anxiety and quality of life

NCT ID: NCT02524444 Completed - Clinical trials for Malaria in Pregnant HIV + Patients

A Comparative Study of Mefloquine and S-P as Prophylaxis Against Malaria in Pregnant HIV + Patients

Start date: September 2015
Phase: Phase 1
Study type: Interventional

Randomized controlled single blind prospective comparative study.

NCT ID: NCT02404233 Not yet recruiting - HIV Positive Clinical Trials

Open Label, Pilot Study of Darunavir Boosted by Cobicistat in Combination With Rilpivirine to Treat HIV+ Naïve Subjects

PREZENT
Start date: March 2015
Phase: Phase 4
Study type: Interventional

Current HIV treatment guidelines recommend the use of triple-drug therapy (two nucleoside reverse transcriptase inhibitors and either a protease inhibitor, non-nucleoside reverse transcriptase inhibitor, or an integrase inhibitor) for the treatment of antiretroviral (ARV)-naïve patients. With the introduction of highly active antiretroviral therapy (HAART), patients with HIV are living much longer. With the increasing lifespan of persons with HIV, long-term complications from therapy as well as the occurrence of co-morbidities with aging have prompted HCPs to re-think the current treatment paradigm and consider novel combinations of ARVs. All of the currently approved HIV antiretrovirals have been implicated in causing long-term toxicities; however the greatest body of evidence for long-term metabolic effects has implicated the nucleoside reverse transcriptase (NRTI) class. By utilizing a non-NRTI treatment regimen, it is hypothesized that many of these long-term metabolic effects (renal toxicity, bone loss, body fat changes) can be delayed or avoided altogether. The clinical data on novel combinations is currently limited but rapidly growing and has included several combinations that have utilized darunavir. This study will be the first of its kind using the unique combination of darunavir/cobicistat and rilpivirine. Currently, this drug combination is not a recommended option for first time treatment of HIV

NCT ID: NCT02371265 Completed - HIV Clinical Trials

Early ART Initiation Among HIV-positive Pregnant Women in Central Mozambique

Start date: April 2012
Phase: N/A
Study type: Interventional

The overall objective of the study is to develop and test a pilot intervention in central Mozambique to implement the new WHO "Option B+" guidelines that seek to increase the proportion of HIV-positive pregnant women in six antenatal care clinics who start antiretroviral therapy (ART) prior to delivery, and are retained in care after 90- days.

NCT ID: NCT02338024 Completed - HIV Clinical Trials

Enhancing Linkage to HIV Care for Newly Detected HIV-positive Persons in Ukraine

MARTAS
Start date: October 22, 2015
Phase: N/A
Study type: Interventional

This study proposes to assess whether a modified Antiretroviral Treatment Access Study intervention, proved to be effective in the U.S. and based on the nurse case management approach, can impact the enrollment in HIV care of recently detected HIV-positive patients in specialized health care clinics in three regions in Ukraine, using the existing local infrastructure. The proposed study addresses a significant public health issue of non-/late enrollment of HIV-positive persons in HIV care and treatment.

NCT ID: NCT02276326 Completed - HIV Seropositivity Clinical Trials

Effects of VSL#3 on Neuro-cognitive Profile of HIV Patients

Start date: July 2014
Phase: N/A
Study type: Interventional

Aim of the study is to evaluate the effects of a change in the intestinal microflora on the neuro-cognitive profile of patients with HIV infection receiving HAART treatment. Improvements will be evaluated with questionnaires on Quality of life and Cognitive and Behavior function. 20 patients will be enrolled and will receive 4 sachets of VSL#3 per day.